Prestige Consumer Healthcare is expected to report Q3 2026 consensus revenue of $329.15 million and EPS of $1.06, with the current stock price of $48.23 trading significantly below the average analyst price target of $67.80.
Investors are primarily focused on the company's organic revenue growth and the continued integration of recent high-profile acquisitions, specifically Breathe Right and LaCorium Health. Recent performance has been driven by strong expansion in the gastrointestinal and dermatological categories, which helped mitigate persistent headwinds in the eye care segment. Analysts will also be monitoring management's progress on debt deleveraging and any potential updates to the full-year 2027 outlook following a robust start to the fiscal year.